These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38718774)
21. Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta-analysis of randomized controlled trials. Heymann M; Schorer R; Putzu A Acta Anaesthesiol Scand; 2022 Oct; 66(9):1037-1050. PubMed ID: 35788557 [TBL] [Abstract][Full Text] [Related]
22. Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study. Scharf C; Liebchen U; Paal M; Becker-Pennrich A; Irlbeck M; Zoller M; Schroeder I Sci Rep; 2021 May; 11(1):10190. PubMed ID: 33986443 [TBL] [Abstract][Full Text] [Related]
23. Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients. Scandroglio AM; Pieri M; Nardelli P; Fominskiy E; Calabrò MG; Melisurgo G; Ajello S; Pappalardo F Artif Organs; 2021 Sep; 45(9):1097-1103. PubMed ID: 33686696 [TBL] [Abstract][Full Text] [Related]
24. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Schilder L; Nurmohamed SA; Bosch FH; Purmer IM; den Boer SS; Kleppe CG; Vervloet MG; Beishuizen A; Girbes AR; Ter Wee PM; Groeneveld AB; Crit Care; 2014 Aug; 18(4):472. PubMed ID: 25128022 [TBL] [Abstract][Full Text] [Related]
25. Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review. Chang K; Li Y; Qin Z; Zhang Z; Wang L; Yang Q; Geng J; Deng N; Chen S; Su B Front Immunol; 2023; 14():1074465. PubMed ID: 36817416 [TBL] [Abstract][Full Text] [Related]
26. Liver dysfunction associated with artificial nutrition in critically ill patients. Grau T; Bonet A; Rubio M; Mateo D; Farré M; Acosta JA; Blesa A; Montejo JC; de Lorenzo AG; Mesejo A; Crit Care; 2007; 11(1):R10. PubMed ID: 17254321 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Guenter SG; Iven H; Boos C; Bruch HP; Muhl E Pharmacotherapy; 2002 Feb; 22(2):175-83. PubMed ID: 11837556 [TBL] [Abstract][Full Text] [Related]
28. [Application of continuous blood purification in critically ill children]. Zhu Y; Dong Y; Xu DL; Jiang JY; Xu Y Zhongguo Dang Dai Er Ke Za Zhi; 2012 Feb; 14(2):147-9. PubMed ID: 22357477 [No Abstract] [Full Text] [Related]
29. CytoSorb purification in critically ill SARS-CoV-2 patients. Pieri M; Fominskiy E; Nardelli P; Bonizzoni MA; Scandroglio AM Int J Artif Organs; 2022 Feb; 45(2):216-220. PubMed ID: 34702109 [TBL] [Abstract][Full Text] [Related]
30. Extracorporeal CO2 removal--a way to achieve ultraprotective mechanical ventilation and lung support: the missing piece of multiple organ support therapy. Gramaticopolo S; Chronopoulos A; Piccinni P; Nalesso F; Brendolan A; Zanella M; Cruz DN; Ronco C Contrib Nephrol; 2010; 165():174-184. PubMed ID: 20427968 [TBL] [Abstract][Full Text] [Related]
31. CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial. Stockmann H; Keller T; Büttner S; Jörres A; Kindgen-Milles D; Kunz JV; Leebmann J; Spies C; Träger K; Treskatsch S; Uhrig A; Willam C; Enghard P; Slowinski T; Trials; 2020 Jun; 21(1):577. PubMed ID: 32586396 [TBL] [Abstract][Full Text] [Related]
32. Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry. Hayanga JWA; Song T; Durham L; Garrison L; Smith D; Molnar Z; Scheier J; Deliargyris EN; Moazami N Crit Care; 2023 Jun; 27(1):243. PubMed ID: 37337243 [TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of hemofiltration without anticoagulation in critically ill patients at high risk of bleeding]. Yang RL; Liu DW Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):651-5. PubMed ID: 18051723 [TBL] [Abstract][Full Text] [Related]
35. Blood Purification Techniques for Sepsis and Septic AKI. Girardot T; Schneider A; Rimmelé T Semin Nephrol; 2019 Sep; 39(5):505-514. PubMed ID: 31514914 [TBL] [Abstract][Full Text] [Related]
36. A Review of Extracorporeal Blood Purification Techniques for the Treatment of Critically Ill Coronavirus Disease 2019 Patients. Niazi NS; Nassar TI; Stewart IJ; Honore PM; Sharma K; Chung KK ASAIO J; 2022 Oct; 68(10):1219-1227. PubMed ID: 35417433 [TBL] [Abstract][Full Text] [Related]
37. [Early use of polymyxin B in sepsis]. Nalesso F G Ital Nefrol; 2012; 29 Suppl 54():S64-6. PubMed ID: 22388833 [TBL] [Abstract][Full Text] [Related]
38. Validity of low-efficacy continuous renal replacement therapy in critically ill patients. Kawarazaki H; Uchino S Anaesthesiol Intensive Ther; 2016; 48(3):191-6. PubMed ID: 27240969 [TBL] [Abstract][Full Text] [Related]
39. Reply to Supady et al. Comment on: Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry. Hayanga JWA Crit Care; 2023 Nov; 27(1):421. PubMed ID: 37919758 [No Abstract] [Full Text] [Related]
40. Organ crosstalk in critically ill patients: hemofiltration and immunomodulation in sepsis. Schefold JC; Hasper D; Jörres A Blood Purif; 2009; 28(2):116-23. PubMed ID: 19506367 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]